ReviewCureus2025
Comparative Effectiveness of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors Versus Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Heart Failure With Reduced Ejection Fraction: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality worldwide, despite advancements in pharmacotherapy. Among the most significant recent developments are sodium-glucose co-transporter 2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs), both of which have demonstrated substantial improvements in clinical outcomes. This systematic review aimed to compare the efficacy, clinical outcomes, and therapeutic value of SGLT2 inhibitors versus ARNIs while also exploring their potential synergistic effects in the treatment of HFrEF. A comprehensive literature search was conducted across PubMed, Scopus, Embase, and Cochrane Central, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and included randomized controlled trials published within the last 10 years. Five high-quality studies met the strict inclusion criteria, reflecting the limited but robust available evidence. The results suggest that both drug classes are effective in reducing cardiovascular death and heart failure hospitalizations, with emerging evidence indicating that their combined use may further enhance clinical outcomes. SGLT2 inhibitors have shown consistent benefits across key endpoints, even when used alongside ARNI therapy. The review highlights favorable safety profiles for both drug classes and supports early combination therapy in suitable patient populations. Observations regarding potential synergistic effects emerged from consistent trends across studies rather than being predefined primary outcomes. These findings reinforce current guideline recommendations advocating for multidrug strategies and emphasize the need for future direct comparative trials to optimize treatment sequencing in HFrEF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.